Society of Infectious Diseases Pharmacists | Strategic Alliance Partners

Advances in antibiotic and microbiome-based therapies may reduce recurrence and improve outcomes in patients with recurrent Clostridioides difficile infection. 

The inaugural Joint MAD-ID/SIDP Annual Meeting was a celebration of learning and networking and focused on the educational needs of infectious diseases pharmacist specialists.

Recent randomized trials and CDC guidance support doxycycline postexposure prophylaxis as a targeted strategy to reduce bacterial STIs in high-risk populations.

McCreary and Dudley emphasize the role of pharmacists when optimizing antimicrobial use, supporting patient care across diverse settings, and driving education, research, and policy.

Experts describe how infectious disease pharmacists drive antimicrobial stewardship, tackle resistance, and shape global training as SIDP marks 35 years.

Using PEPFAR-backed HIV treatment in Zambia as minerals leverage will risk resistance, deaths, and US global health leadership.

Improved risk stratification for coadministration of linezolid with serotonergic agents has the potential to optimize its indications in clinical practice.

Interest in intravenous push administration of antibiotics is regaining popularity as fluid shortages arise.

The CLEAR framework helps guide pharmacists during the process of assessing and delabeling β-lactam allergies to improve patient outcomes.

Pharmacists play a critical role in optimizing triazole therapy in preventing and managing invasive fungal infections.

Cephalosporins are commonly prescribed in the outpatient setting; understanding differences among them is important for pharmacists.

Cefepime-taniborbactam shows promise against resistant infections, but more studies are needed.

As HIV treatment and prevention evolve, the use of long-acting injectables and their role in combating the HIV epidemic grows.

The agency outlines key elements for building effective hospital sepsis programs.

Incorporating AI into pharmacy education is crucial to training on its appropriate use.

Medication therapy management reimbursement can be a driving factor to work toward statin implementation in this patient group.

Pharmacy personnel can be integrated to optimize antimicrobial use.

Outpatient ASPs remain crucial amid rising antimicrobial resistance.

Pharmacists can also ensure proper education and selection of therapy before and after discharge.

Older adults without a Part D plan face costs ranging from $180 to $295 per shot.

Regardless of a pharmacist’s practice site or type, they play an integral role in ensuring the treatment success of patients with HIV.

Pharmacists involvement in HIV care and treatment has been shown to lead to clinically and statistically significant improvements in ART adherence, as well as greater viral load suppression for patients with HIV.

Pharmacists play a vital role in HIV care by addressing social determinants of health, managing complex HIV medication regimens, and providing comprehensive patient counseling.

This step-by-step primer describes the implementation process for β-lactam TDM.

Data show these cases pose some of the most significant threats to patients and health systems.

Delivery, manufacturing concerns hinder green light from US Agency, but European Medicines Agency approves treatment.

Continued advancements in therapy may expand its use to larger patient population, though challenges remain

Vaccination provides an opportunity to prevent and treat herpes simplex virus infection.

Pediatric guidelines suggest 10 days of therapy for community-acquired pneumonia, but recent data support shortening therapy duration.

Outpatient treatment is primarily based on patient-specific factors, whereas oseltamivir remains the therapy of choice for inpatient settings.